Taxol Adjuvant Benefit In Receptor-Positive Breast Cancer Not Yet Clear
Executive Summary
Bristol-Myers Squibb's Taxol (paclitaxel) approval for sequential adjuvant therapy allows for use of the drug in estrogen and progesterone receptor-negative and positive tumors, although no benefit has been made clear in the receptor-positive group.